Drug & Biological Products

In the challenging world of biopharmaceutical development, companies need a trusted regulatory partner to help them make timely, informed decisions. Greenleaf’s respected FDA experts provide a vital perspective to clients on the complex process of bringing new therapeutics to market.

Our Drug & Biological Products Services

Strategic Regulatory Guidance


Greenleaf experts specialize in providing strategic and technical guidance on medical product development, regulatory review, and postmarket requirements. Our strategic consultation encompasses:

  • FDA regulatory programs and procedures
  • Product development
  • Endpoint and biomarker selection, development, and regulatory review
  • Use of real-world evidence in regulatory submissions
  • Premarket review processes
  • Postmarket safety requirements
  • Pipeline decisions and optimization

Premarket Review Process


Drawing on deep knowledge cultivated during their careers as FDA leaders and senior officials, Greenleaf’s advisors deliver analysis and guidance on an array of issues companies face throughout the premarket review process, including:

  • Scientific and regulatory practices for clinical programs and regulatory submissions
  • Identification of and eligibility for special designations, such as breakthrough therapy designation, RMAT, fast track, and accelerated approval
  • Preparation for FDA milestone meetings, including EOP2, pre-filing, mid-cycle review, and end-of-review meetings
  • Advisory committee meetings and decisions
  • FDA communications, including formal, in-person, and regulatory correspondence

Regulatory Policy Services


Greenleaf’s team includes regulatory policy experts with extensive experience providing insight and recommendations to small and large companies, trade associations, patient organizations, and other stakeholders on:

● FDA regulatory policy, including novel programs
● Product designations and access to expedited programs
● Regulatory issues arising both pre and post market
● Regulatory intelligence and scientific policy
● Building client capacity and understanding of regulatory policy issues

Learn more about Greenleaf’s Regulatory Policy services

Pipeline Review Services


Our team’s multidisciplinary expertise helps companies evaluating and prioritizing their drug development pipeline to understand and effectively manage regulatory risk. We provide pipeline evaluations, gap analyses, and customized strategies for:

  • Managing regulatory risk and reducing regulatory uncertainties
  • Planning and decision-making related to clinical programs and regulatory approval
  • Prioritizing and addressing programmatic needs for individual candidates and across the portfolio, based on systematic gap analysis
  • Drug development options, opportunities, and benchmarks

Marketing & Promotional Practices


Greenleaf supports drug and biologics clients with strategic review and guidance related to:

  • Labeling requirements
  • Promotional materials
  • Direct-to-consumer advertising review processes
  • Use of social media
  • Remediation of untitled and warning letters

Cell and Gene Therapy


The Drug and Biological Products Team assists sponsors of cell and gene therapies with FDA interactions and submissions — including early INTERACT and pre-IND meetings; requests for orphan drug, RMAT, and rare pediatric disease designations; and data comparability questions — and helps to clarify FDA requirements for specific types of cellular products. The team also provides guidance on how to maximize clinical trial design for cell and gene therapies to treat rare and ultra-rare diseases.  

Learn more about Greenleaf’s Cell and Gene Therapy services

Advisory Services


Experts from the Drug and Biological Products Team provide advisory services that include extensive research and due diligence for investors engaged in potential deals that require regulatory risk analyses before and after decisions and transactions.

Learn more about Greenleaf’s Advisory services

Success Stories

  • Restarting a Stalled Development Program

    Greenleaf Health worked with a multinational biopharmaceutical manufacturer to reinitiate their phase 3 program for a women’s health product, which had stalled after the FDA had voiced concerns with the design of the pivotal trial. The client needed a way to fulfill the Agency’s request for additional long-term outcomes data, which would require an expansion …

  • Leading a Client Through Dispute Resolution to Product Approval

    Upon receiving a Complete Response Letter (CRL) for their lead product to manage mild to moderate pain, a mid-sized specialty pharmaceutical company engaged Greenleaf Health to assist them in addressing the deficiencies cited in the CRL and developing a strategy for resubmitting the new drug application (NDA).  Greenleaf’s regulatory experts, in conjunction with a partner …

  • Developing a Regulatory Strategy to Successfully Manage Assessment and Conduct of a Large Phase 3 Program

    Greenleaf Health assisted a mid-sized pharmaceutical company in developing a regulatory strategy to address safety and trial conduct issues in the phase 3 program for their lead compound for cardiovascular disease. During phase 3 trials, the client identified a consequential safety event and sought Greenleaf’s guidance on both addressing the safety event in the context …

Drug and Biological Product Resources

View or download the PDFs below to learn more about Greenleaf and our drug and biological product capabilities.

Connect With an Expert

Greenleaf’s Drug & Biological Products Team is ready to help you achieve your regulatory goals. Please provide the information below and a team member will be in contact.

Connect with Expert - Drugs